Daewoong Pharmaceutical-Genomictree, Overseas Sales of COVID-19 Diagnostic Kits

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 27th that it has signed a global sales and supply agreement for the novel coronavirus disease (COVID-19) molecular diagnostic kit 'Acuraditek,' developed by early cancer diagnosis company Genomictree.

Acuraditek uses gene amplification technology to explosively increase viral genes for detection, resulting in high sensitivity and specificity. Results can be confirmed within 4 hours after specimen collection.

Daewoong Pharmaceutical plans to pursue overseas approval for Acuraditek by utilizing its overseas branch corporations and partner networks. Export negotiations will be conducted focusing on countries where the number of COVID-19 diagnostic patients has recently surged, such as the United States, Latin America, and the Middle East.

Acuraditek has currently obtained European in vitro diagnostic certification (CE-IVD), emergency use authorization in Peru and Singapore, and has applied for emergency use authorization in multiple overseas countries including the United States, India, Saudi Arabia, Malaysia, Brazil, Canada, and Indonesia.

Jeon Seung-ho, CEO of Daewoong Pharmaceutical, said, "Based on our global business capabilities, we have started collaboration with Genomictree to expand overseas supply of COVID-19 diagnostic kits," adding, "Along with the development of COVID-19 therapeutics currently underway such as 'Niclosamide' and 'Camostat,' we will provide comprehensive measures to overcome COVID-19."

This content was produced with the assistance of AI translation services.